Covered recipient · General Payments record
NATASHA FUKSINA
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$1,329.37
- Reported across 77 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $196.16 | 11 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $46.29 | 3 |
| Phadia US Inc. | $33.96 | 1 |
| Lilly USA, LLC | $31.83 | 2 |
| Abbott Laboratories | $18.17 | 1 |
| OptiNose US, Inc. | $18.03 | 1 |
| Cleerly, Inc. | $17.07 | 1 |
| AIMMUNE THERAPEUTICS, INC. | $16.37 | 1 |
| Acella Pharmaceuticals, LLC | $14.44 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (11)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $18.17 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124815405 | CMS |
| Acella Pharmaceuticals, LLC | $14.44 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126636340 | CMS |
| AIMMUNE THERAPEUTICS, INC. | $16.37 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147000943 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.26 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104302356 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.37 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104713053 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.66 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105500706 | CMS |
| Cleerly, Inc. | $17.07 | 09/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144711686 | CMS |
| Lilly USA, LLC | $15.70 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135271710 | CMS |
| Lilly USA, LLC | $16.13 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135236372 | CMS |
| Optinose US, Inc. | $18.03 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142189472 | CMS |
| Phadia US Inc. | $33.96 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1067584178 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.